Skip to main content
Premium Trial:

Request an Annual Quote

Swedish Pharma Firm Selects Certara's Software for Drug Discovery

Premium

Certara said this week that Medivir, a Swedish pharmaceutical company that focuses on infectious diseases such as hepatitis C, has selected its D360 software as its global drug discovery platform.

According to Certara, Medivir will use D360 — an integrated solution for querying, analyzing, and visualizing drug discovery data — to deliver chemical structure and biological assay data and analytic tools to its discovery chemists and biologists based in Stockholm and Cambridge, UK.

Peter Lind, Medivir's informatics manager, said in a statement that his firm selected Certara's product because it needed a flexible solution "that would allow our discovery scientists to collaborate more effectively, and make informed decisions using all the available data."

The financial details of the agreement were not disclosed.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.